Bladder Cancer: Highlights from 2006 Antonio Alcaraz  European Urology Supplements  Volume 6, Issue 12, Pages 737-744 (July 2007) DOI: 10.1016/j.eursup.2007.03.015 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Cancer-free survival rate after treatment with Bacillus Calmette-Guérin (BCG)+interferon-alpha (IFN-α) is similar in BCG-naïve patients (BCG-N) and patients with recurrent bladder cancer after 12 mo of remission. * Versus BCG-N patients. European Urology Supplements 2007 6, 737-744DOI: (10.1016/j.eursup.2007.03.015) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Results from interactive voting on a representative case (details: see text) indicate that six instillations of Bacillus Calmette-Guérin (BCG) therapy and cystectomy are the favoured treatment options, whereas BCG+interferon-alpha (IFN-α) and optimised mitomycin therapy are less chosen therapies. European Urology Supplements 2007 6, 737-744DOI: (10.1016/j.eursup.2007.03.015) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Results from interactive voting indicate that approximately an equal amount of participants chose between chemotherapy (chemo), Bacillus Calmette-Guérin (BCG) therapy, or a combination of both as the treatment option for a patient with bladder cancer previously treated with BCG (details outlined in text), whereas radical cystectomy was a less favoured option. European Urology Supplements 2007 6, 737-744DOI: (10.1016/j.eursup.2007.03.015) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Bladder recurrence, local recurrence, distant metastases and disease-free 2-yr survival rates after laparoscopic nephroureterectomy (LNU) and open nephroureterectomy (ONU) are comparable. European Urology Supplements 2007 6, 737-744DOI: (10.1016/j.eursup.2007.03.015) Copyright © 2007 European Association of Urology Terms and Conditions